STGI Announces Georgetown University ResearchersReport ANTICORT a New Way to Control Excess...

Business Editors/Health & Medical Writers

LAS VEGAS--(BUSINESS WIRE)--June 13, 2000

(TRADEGATE-SSJ-920435) Steroidogenesis Inhibitors International, Inc. (OTCBB:STGI-news) is pleased to announce that in a press release issued today, Scientists at Georgetown University Medical

Elevated levels of cortisol, mainly induced by stress, have been implicated in the development of numerous diseases, including depression, Alzheimer's, HIV, etc. Using the drug ANTICORT(TM), Dr. Papadopoulos and his group from the Division of Hormone Research found that they could control the hormone and stress-induced cortisol production by human adrenal cells.

"Although more work is needed to understand how Anticort(TM) works, these results clearly indicate that we have now a powerful tool to control the stress response and its detrimental effects on the body" says Dr. Papadopoulos. Anticort(TM) is a proprietary preparation developed by Alfred T Sapse, M.D. Chairman of Steroidogenesis Inhibitors International Inc. (STGI-OTC.BB). An FDA IND has been obtained and clinical trials are in progress to examine the immunoprotective effect of Anticort(TM) in HIV patients.

Bert Wollen, CEO of STGI commented, "This is exciting news for the company. We may have a means to help millions of people to live a longer life unencumbered by deadly diseases. "

Dr. Alfred Sapse further stated, "This is a wonderful day for STGI, that all of the years of hard work by our company, our drug ANTICORT(TM) is starting to be proven for its potential health benefits, especially because they are coming from a renown University research facility."

STGI is a pharmaceutical company with its core technology being ANTICORT(TM), which is currently in FDA Phase 1B/2A clinical trials as an anticortisol drug for the treatment of HIV positives.

This Release Contains Statements About the Future That Could Differ From Actual Results. the Statements are Subject to Risk and Uncertainties, Including, But Not Limited To, the Impact of Competition, Fluctuations in Stock Price and Liquidity, Fluctuating Operating Results and Other Risks.